ClinicalTrials.gg
CompletedNCT00862849Updated Jul 22, 2014Results posted

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

A Phase 1 interventional study of Insulin Lispro and Regular Human Insulin in Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-22.

Sponsored by Halozyme Therapeutics · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
1,995th of 2,501
22 · median 82
Started
2009
with 162 others
Phase 1
204 of 3,022
13 open now
Registered
806th of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,995th largest by enrollment of the 2,501 interventional ones that give a count, is one of 163 that started in 2009, is one of 204 in phase 1, and was the 806th registered.

Diabetes Mellitus

8,292 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

Insulin lispro and regular human insulin are Food and Drug Administration (FDA)-approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both insulin lispro and regular human insulin in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.

Read the detailed description

The purpose of this study is to compare the pharmacokinetics (absorption, distribution, breakdown and elimination) of regular human insulin + recombinant human hyaluronidase (rHuPH20) versus insulin lispro alone, and to compare the pharmacokinetics of insulin lispro + rHuPH20 versus insulin lispro alone. The effects of regular human insulin + rHuPH20, insulin lispro + rHuPH20, and insulin lispro alone on the body will be evaluated by blood glucose measurements and by calculating the rate at which a glucose solution is infused to maintain blood glucose within a certain range. The safety and tolerability of insulin lispro with and without rHuPH20 and regular human insulin with rHuPH20 will be studied. The study drugs will be administered by subcutaneous (under the skin) injection.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • rHuPH20
  • Recombinant Human Hyaluronidase
  • Insulin Lispro
  • Regular Human Insulin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants between the ages of 18 and 55 years, inclusive. (Healthy is defined as no abnormalities.)
  • (BMI) between 18-27 kilograms per meter squared (kg/m\^2), inclusive.
  • Total body weight >65 kilograms (kg) (143 pounds [lb]) for men and >46 kg (101 lb) for women.
  • Decision making capacity and willingness to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including adequate venous access.
  • Vital signs (blood pressure, pulse rate, body temperature) within normal range or, if out of range, assessed by the Principal Investigator (PI) as not clinically significant (NCS).
  • Fasting blood glucose level \<100 milligrams per deciliter (mg/dL) at screening.
  • A negative serum pregnancy test (if female of ).
  • Female participants of childbearing potential must agree to be practicing effective or abstinence currently and agree to continue to do so for the duration of their time on study.
  • Signed, written Institutional Review Board (IRB)-approved .

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, oncologic, or neurologic (to include history of seizures) disease; hypoglycemic episodes; intercurrent illness (such as influenza); or allergic disease (including severe drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Clinical significance to be determined by the PI.
  • As judged by the Investigator, clinically significant findings in routine laboratory data. (Anemia with hematocrit less than 33% at screening is specifically exclusionary.)
  • Known history of diabetes mellitus (type 1 or type 2) or gestational diabetes.
  • Known allergy to hyaluronidase or any other ingredient in the study drug.
  • Positive (HIV 1) antibody test, (anti-hepatitis B surface antigen [anti-HBsAg]) or (anti-hepatitis C virus [anti-HCV]) antibody test.
  • History or evidence of alcohol or drug abuse.
  • History or evidence of use of any tobacco or nicotine-containing product within 6 months of screening and a screening qualitative urine nicotine test.
  • Use of drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action or glucose utilization.
  • Donation of blood in excess of 500 milliliters (mL) within 56 days before dosing.
  • Participation in a study of any drug or device 30 days before enrollment in this study.
  • The participant is unfit for the study in the opinion of the Investigator.
  • Women who are pregnant or breast-feeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Insulin Lispro, Regular Human Insulin, rHuPH20

    All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20) Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20 Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone There was a washout period of 3 to 14 days between interventions. The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections.

    Drug: Insulin Lispro · Drug: Regular Human Insulin · Drug: rHuPH20

Interventions

06

What researchers measure

Primary outcomes

  1. Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T])

    Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); and every 5 mins (from 15 to 30 mins) after each injection. The percent coefficient of variation (CV%) was calculated as 100\*(standard deviation/mean). The intra-participant CV% was calculated directly from the 2 replications of each treatment. The CV% for percentage of total AUC is reported from 0 to 30 minutes.

    Time frame: predose up to 30 minutes postdose

Secondary outcomes

  1. Time to Early and Late 50% Maximum Serum Insulin Concentration (t[50%Max])

    Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.

    Time frame: predose up to 480 minutes postdose

  2. Peak Serum Insulin Concentration (Cmax)

    Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.

    Time frame: predose up to 480 minutes postdose

  3. Time to Percentage of Total Glucose Infused

    Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection. Time to 25%, 50%, and 75% of total glucose infused are summarized.

    Time frame: predose up to 480 minutes postdose

  4. Percentage of Total Glucose Infused

    Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); and every 30 mins (from 90 to 240 mins) after each injection. Percentage of total glucose infused from 0 to 4 hours is summarized.

    Time frame: predose up to 240 minutes postdose

  5. Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

    The number of TEAEs related to study drug (as determined by the Investigator) are summarized. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: first dose through 7 to 10 days after last dose

07

Results

Posted Jul 11, 2014

Participant flow

Intervention 1
Participant flow — Intervention 1
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started353443
Received at least one dose of study drug353443
Completed353443
Not completed000000
Washout 1 (3 to 14 Days)
Participant flow — Washout 1 (3 to 14 Days)
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started353443
Completed343443
Not completed010000
Withdrew: Withdrawal by subject010000
Intervention 2
Participant flow — Intervention 2
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started343443
Completed343443
Not completed000000
Washout 2 (3 to 14 Days)
Participant flow — Washout 2 (3 to 14 Days)
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started343443
Completed333443
Not completed010000
Withdrew: Protocol violation010000
Intervention 3
Participant flow — Intervention 3
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000
Washout 3 (3 to 14 Days)
Participant flow — Washout 3 (3 to 14 Days)
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000
Intervention 4
Participant flow — Intervention 4
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000
Washout 4 (3 to 14 Days)
Participant flow — Washout 4 (3 to 14 Days)
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000
Intervention 5
Participant flow — Intervention 5
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000
Washout 5 (3 to 14 Days)
Participant flow — Washout 5 (3 to 14 Days)
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000
Intervention 6
Participant flow — Intervention 6
MilestoneLispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro AloneLispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro AloneRHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20
Started333443
Completed333443
Not completed000000

Outcome measures

PrimaryIntra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T])

Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); and every 5 mins (from 15 to 30 mins) after each injection. The percent coefficient of variation (CV%) was calculated as 100\*(standard deviation/mean). The intra-participant CV% was calculated directly from the 2 replications of each treatment. The CV% for percentage of total AUC is reported from 0 to 30 minutes.

Time frame:
predose up to 30 minutes postdose
Reported as:
Mean · percentage of coefficient of variance
Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T])
percentage of coefficient of varianceInsulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T])14.04 ± 11.1223.81 ± 12.4340.51 ± 24.30
Statistical analysis
  • Insulin Lispro + rHuPH20 vs Insulin Lispro Alone · Mixed Models Analysis · p = <0.0001 (Treatment comparison for %AUC(0-30). Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Ls mean difference: 26.47 · 90% CI 18.22 to 34.71Analysis performed using mixed model with fixed effect for treatment. A compound symmetry covariance matrix among repeated measurements was assumed.
  • Regular Human Insulin + rHuPH20 vs Insulin Lispro Alone · Mixed Models Analysis · p = 0.0015 (Treatment comparison for %AUC(0-30). Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Ls mean difference: 16.70 · 90% CI 8.45 to 24.94Analysis performed using mixed model with fixed effect for treatment. A compound symmetry covariance matrix among repeated measurements was assumed
SecondaryTime to Early and Late 50% Maximum Serum Insulin Concentration (t[50%Max])

Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.

Time frame:
predose up to 480 minutes postdose
Reported as:
Mean · minutes
Time to Early and Late 50% Maximum Serum Insulin Concentration (t[50%Max])
minutesInsulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
early t(50%max)14.14 ± 3.0121.52 ± 4.9524.73 ± 5.16
late t(50%max)88.14 ± 16.96136.67 ± 27.16144.43 ± 31.79
SecondaryPeak Serum Insulin Concentration (Cmax)

Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.

Time frame:
predose up to 480 minutes postdose
Reported as:
Mean · picomoles per liter (pmol/L)
Peak Serum Insulin Concentration (Cmax)
picomoles per liter (pmol/L)Insulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
Peak Serum Insulin Concentration (Cmax)782.85 ± 199.84561.93 ± 141.88482.40 ± 119.50
SecondaryTime to Percentage of Total Glucose Infused

Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection. Time to 25%, 50%, and 75% of total glucose infused are summarized.

Time frame:
predose up to 480 minutes postdose
Reported as:
Mean · minutes
Time to Percentage of Total Glucose Infused
minutesInsulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
25%72.38 ± 12.5091.58 ± 15.8599.13 ± 19.26
50%118.95 ± 22.93142.55 ± 21.31156.83 ± 30.36
75%179.23 ± 40.73203.15 ± 31.12222.48 ± 44.44
SecondaryPercentage of Total Glucose Infused

Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); and every 30 mins (from 90 to 240 mins) after each injection. Percentage of total glucose infused from 0 to 4 hours is summarized.

Time frame:
predose up to 240 minutes postdose
Reported as:
Mean · percentage of total glucose infused
Percentage of Total Glucose Infused
percentage of total glucose infusedInsulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
Percentage of Total Glucose Infused88.70 ± 9.0485.17 ± 7.8979.81 ± 11.27
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

The number of TEAEs related to study drug (as determined by the Investigator) are summarized. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
first dose through 7 to 10 days after last dose
Reported as:
Number · events
Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
eventsInsulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug103

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Lispro + rHuPH20—0/22 (0%)4/22 (18.2%)
Regular Human Insulin + rHuPH20—0/20 (0%)4/20 (20%)
Insulin Lispro Alone—0/21 (0%)9/21 (42.9%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventInsulin Lispro + rHuPH20Regular Human Insulin + rHuPH20Insulin Lispro Alone
Catheter site painGeneral disorders2/221/202/21
Injection site haemorrhageGeneral disorders0/220/202/21
Iron deficiency anaemiaBlood and lymphatic system disorders0/221/200/21
Pain in extremityMusculoskeletal and connective tissue disorders0/221/201/21
HeadacheNervous system disorders0/221/201/21
VomitingGastrointestinal disorders0/220/201/21
Injection site irritationGeneral disorders0/220/201/21
Upper respiratory tract infectionInfections and infestations1/220/201/21
Thermal burnInjury, poisoning and procedural complications0/220/201/21
Flank painMusculoskeletal and connective tissue disorders0/220/201/21

Baseline characteristics

Participants who received at least one dose of insulin lispro, regular human insulin, or recombinant human hyaluronidase (rHuPH20).

Age, Continuous
Age, Continuous(years)All Participants
Mean35.9 ± 9.24
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female10
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White19
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino5
Not Hispanic or Latino17
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Participants
United States22
08

Study locations

1 site
  • Profil Institute for Clinical Research, Inc.
    Chula Vista, California 91911, United States
09

References and documents

Publications

  • Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther. 2011 Oct;13(10):1039-45. doi: 10.1089/dia.2011.0115. Epub 2011 Jun 29. PubMed 21714645 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jun 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2009
First posted
Mar 17, 2009
Start
Mar 2009
Primary completionActual
Jun 2009
CompletionActual
Aug 2009
Results first posted
Jul 11, 2014
Last update
Jul 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00862849
Responsible party
Sponsor
First posted
Mar 17, 2009
Start date
Mar 2009
Primary completion
Jun 2009
Completion
Aug 2009
Results posted
Jul 11, 2014
Last update
Jul 22, 2014

Study contacts

Linda A Morrow, M.D.
principal investigator · Profil Institute for Clinical Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion